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Introduction: Antibiotic-associated diarrhea (AAD) is common and frequently more severe
in hospitalized elderly adults. It can lead to increased use of healthcare resources. We
estimated the cost-effectiveness of a fermented milk (FM) with probiotic in preventing
AAD and in particular Clostridium difficile-associated diarrhea (CDAD).
Methods: Clinical effectiveness data and cost information were incorporated in a model
to estimate the cost impact of administering a FM containing the probiotic Lactobacillus
paracasei ssp paracasei CNCM I-1518 in a hospital setting. Preventing AAD by the
consumption of the probiotic was compared to no preventive strategy.
Results: The probiotic intervention to prevent AAD generated estimated mean cost
savings of £339 per hospitalized patient over the age of 65 years and treated with
antibiotics, compared to no preventive probiotic. Estimated cost savings were sensitive
to variation in the incidence of AAD, and to the proportion of patients who develop
non-severe/severe AAD. However, probiotics remained cost saving in all sensitivity
analyses.
Conclusion: Use of the fermented dairy drink containing the probiotic L. paracasei CNCM
I-1518 to prevent AAD in older hospitalized patients treated with antibiotics could lead to
substantial cost savings.
Keywords: antibiotic-associated diarrhea, Clostridium difficile, hospitalized elderly, probiotics, cost effectiveness,
nutrition economics
INTRODUCTION
ETIOLOGY AND EPIDEMIOLOGY OF ANTIBIOTIC-ASSOCIATED
DIARRHEA
Antibiotic-associated diarrhea (AAD) is a form of diarrhea that
occurs during or shortly after administration of an antibiotic,
and is diagnosed in the absence of other known causes of diar-
rhea. The rate of occurrence varies among reports, with a range
of 1–44%, depending on the population and type of antibiotic
(Bergogne-Berezin, 2000; Graul et al., 2009). Adults over the age
of 65 years are known to be at the top end of this range (Kyne,
2010; Bauer et al., 2011), and broad spectrum antibiotics impart
a greater risk than narrow spectrum, in particular clindamycin,
cephalosporins, and fluoroquinolones. One aspect of AAD that
compels us to take this problem seriously is the occurrence of
Clostridium difficile-associated diarrhea (CDAD), also referred to
as C. difficile infection, in elderly hospitalized patients. CDAD is
responsible for around 10–25% of all cases of AAD and it can
occur up to 8 weeks after antibiotic therapy (Bartlett and Gerding,
2008).
TREATMENT OF AAD
AAD is treated by withdrawal of the precipitating antibiotic,
avoidance of antiperistaltic agents, rehydration and, if neces-
sary replacement of the provocative agent by a more appropriate
antibiotic, which has a lesser risk of induction of diarrhea (Cohen
et al., 2010). Clinical resolution is observed in the majority
of patients who respond well to these treatments but a small
proportion of subjects may develop CDAD. Current guidelines
from ESCMID consider pharmacotherapy of an initial episode of
CDADwith oral metronidazole or oral vancomycin the mainstays
for pharmacological treatment of CDAD (Crobach et al., 2009).
English guidelines recommend oral metronidazole for initial
treatment in these patients, because it is cheaper than oral van-
comycin, and because of the concern that overuse of vancomycin
may result in the selection of vancomycin-resistant enterococci
(Gerding and Gerding, 2005). In patients with severe C. difficile
infection, English guidelines recommend initial treatment with
oral vancomycin, on the basis of evidence from relatively recent
randomized clinical trials (RCTs) that compared vancomycin and
metronidazole, showing a lower rate of treatment failure with
vancomycin in patients with severe C. difficile infection (Louie
et al., 2007; Zar et al., 2007; Bouza et al., 2008).
RECURRENT INFECTION
Recurrence and reinfection is common and can occur in up to
50% of the cases, depending on the antibiotics used (Debast
et al., 2014). Recurrence of CDAD is a serious and difficult-
to-treat problem, impacting on the length and overall cost of
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hospitalization (Pépin et al., 2005a,b; Fitzpatrick and Barbut,
2012). The antibiotic administered to treat the initial episode
may be used for the first recurrence, unless this is metronidazole
and the recurrence meets criteria for severe C. difficile infection.
In second and subsequent recurrences, vancomycin is recom-
mended (Gerding et al., 2008). Fidaxomicin, a novel bactericidal
macrocyclic antibiotic (Drekonja et al., 2011; Cornely, 2012) is
not part of the routine treatment approaches, although it can
be considered in specific situations left to the discretion of the
specialists.
MORTALITY
Mortality due to C. difficile doubled from 1999 to 2004 and con-
tinued to rise until 2007. Since then, great effort has been made
to ensure prevention or optimized care and a decrease was seen
in the UK (Wiegand et al., 2012). However, it is still a significant
cause of AAD, posing a considerable financial burden on health
service providers in both Europe and the USA (Ghantoji et al.,
2010; Wiegand et al., 2012). Evidence suggests that there is an
increasing incidence of CDAD in populations previously thought
to be at low risk (Benson et al., 2007; Honda and Dubberke,
2014). In recent years there has also been an emergence of new
hypervirulent genotypes, in particular the strain BI/NAP1/027,
leading to increased incidence of CDAD, more severe disease,
higher relapse rates, increased mortality, and greater resistance to
fluoroquinolone antibiotics (McDonald et al., 2005; Pépin et al.,
2005a,b; Cartman et al., 2010; Barbut et al., 2011). In 2004, a
prospective study was conducted at 12 Quebec hospitals to deter-
mine the incidence of nosocomial CDAD and its complications
(Loo et al., 2005). A total of 1703 patients with 1719 episodes of
nosocomial CDAD were identified. The incidence was 22.5 per
1000 admissions. The 30-day attributable mortality rate was 6.9
percent.
PREVENTION
English guidelines recommend that healthcare workers wash their
hands before and after contact with patients with suspected or
confirmed C. difficile infection, and that disposable gloves and
aprons are used when handling body fluids and caring for CDAD
patients (National Audit Office, 2004; Department of Health and
Health Protection Agency, 2008). These guidelines also recom-
mend that patients with potentially infective diarrhea should be
moved immediately into a single room with en-suite facilities.
Prevention primarily revolves around control of antibiotic use,
followed by comprehensive infection control procedures once
outbreaks occur.
In parallel, other interventions for the prevention of AAD have
been explored, including the use of probiotic bacteria (Parkes
et al., 2009). Probiotics are defined as “live micro-organisms
which, when administered in adequate amounts, confer a health
benefit on the host” (FAO/WHO, 2001). A number of meta-
analyses of trials with probiotics for prevention of AAD have been
performed (Hempel et al., 2012; Ritchie and Romanuk, 2012;
Videlock and Cremonini, 2012). We only report here the most
recent Cochrane meta-analysis reporting on CDAD (Goldenberg
et al., 2013). The primary objectives were to assess the efficacy and
safety of probiotics for preventing CDAD in adults and children.
Randomized controlled (placebo, alternative prophylaxis, or no
treatment control) trials investigating probiotics (any strain, any
dose) for prevention of CDAD were considered for inclusion. The
analysis (23 trials, 4213 participants) suggests that probiotics sig-
nificantly reduce the risk by 64%. The incidence of CDAD was
2.0% in the probiotic group compared to 5.5% in the placebo
or no treatment control groups (RR 0.36; 95% CI 0.26–0.51).
Adverse events were assessed in 26 studies (3964 participants) and
this analysis indicates that probiotics reduce the risk of adverse
events by 20% (RR 0.80; 95% CI 0.68–0.95). The authors con-
clude that moderate quality evidence suggests that probiotics
are both safe and effective for preventing C. difficile-associated
diarrhea.
ECONOMIC IMPACT
In 2004, the UK health authorities introduced mandatory report-
ing of CDAD in people older than 65 years. The majority of cases
of CDAD are elderly people with prolonged in-patient stays in
a health-care setting. AAD and CDAD have become and remain
a serious problem for health care providers, leading to concerns
around patient safety, and increased medical treatment costs. The
considerable morbidity associated with CDAD results in a high
economic burden, with extended length of hospital stays being
the main cost driver as patients with CDAD spend on average
an extra 7–21 days in hospital, compared with non-infected con-
trols (Campbell et al., 2009; Dubberke and Wertheimer, 2009).
Isolation of the patients who develop CDAD can also represent
a substantial cost, as well as the closing and cleaning of wards.
In addition, there are significant costs associated with treating
recurrent infections. Vonberg et al. (2008) reported an average
cost to treat CDAD of £33,840 per patient. Furthermore, since a
high proportion of CDAD patients are elderly, its economic bur-
den is expected to increase over the coming years as the world’s
population ages (Kuijper et al., 2006).
Based on the Cochrane report that probiotics can be mod-
erately effective in reducing the incidence of CDAD, we may
hypothesize that consumption of a probiotic can reduce the asso-
ciated increased treatment costs and the extended length of stay in
acute health care facilities,if used routinely in elderly patients who
receive antibiotics. Hence the objective of this study was to assess
the health-economic impact of a preventive nutritional strat-
egy using a fermented milk (FM) with probiotic in hospitalized
patients older than 65 years in the UK health care setting.
METHODS
Decision analytic modeling is a well-accepted methodology to
estimate cost-effectiveness and inform budgetary impact analy-
sis of an intervention, including not only outcomes from clinical
trials, but also data provided by other sources of information on
items such as resource utilization, response, and recurrence.
Model design
A model was constructed to estimate the cost consequences of a
FM containing the probiotic Lactobacillus paracasei ssp paracasei
CNCM I-1518 as a preventive intervention in the management of
AAD, from the perspective of the NHS and in line with current
NICE guidelines (NICE, 2008).
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Figure 1 shows the structure of the model. Our model con-
siders a cohort of elderly hospitalized patients over 65 years
of age treated with antibiotics, who may or may not receive
probiotics as preventive treatment. The structure for the sub
model “probiotics” is identical to the displayed structure of
the sub model “no probiotics.” In both groups patients may
develop uncomplicated or complicated diarrhea with a related
mortality risk. When diarrhea occurs, antibiotic treatment is
interrupted or changed, according to the NHS best practice
guidance. The patient may respond, leading to cure of the
diarrhea, or not respond due to treatment failure, leading to
another change of treatment. A proportion of the “cured” patients
at any point in the model will suffer a recurrence after an
initial response. The structure for the sub model “non-C. diff
etiology” is identical to the displayed structure of the sub model
“C. difficile.”
The follow-up time in this model is until recovery or death
during the period of hospitalization, which comprises treat-
ment of AAD, including CDAD and also recurrent infection and
complications.
Study population and comparison
The study population consists of elderly hospitalized patients over
65 years of age being treated with antibiotics. The study pop-
ulation in our model is based on the study populations in the
trials, which provide the clinical input for the model, especially
a clinical trial by Hickson (2007), conducted in England. A recent
study conducted on behalf of the European Center for Disease
Prevention and Control confirmed that age is one of the risk fac-
tors for more severe infection (Bauer et al., 2011). The model
compares the FM with probiotic as preventive management of
AAD, in particular CDAD, with no preventive treatment, accord-
ing to the UK guidelines for pharmacoeconomic research (NICE,
2008).
Clinical outcomes
The model extrapolates the efficacy data from the probiotic
clinical trials on AAD (reduction in the rate of CDAD and non-
CDAD), and other related clinical events (recurrent diarrhea,
complications, and mortality) to calculate overall success rate
(proportion of patients fully recovered).
Study perspective
This analysis was conducted from the perspective of the NHS.
This perspective facilitates comparisons with other UK economic
evaluations. Due to the perspective taken, societal or indirect
costs were not included in the analysis. The cost assessment is
based on the costs for probiotic management of AAD and the cost
associated with treatment of complications.
Data sources
Data sources included published literature, clinical trials, official
price/tariff lists, a Delphi panel study, and national popula-
tion statistics. Characteristics of clinical events are not country-
specific. Hence, data on clinical probabilities were derived from
the international literature (Bouza et al., 2008; Lowy et al., 2010;
Louie et al., 2011).On the other hand, for costs and informa-
tion on therapeutic choices, the general recommendation is that
country-specific data sources should be used whenever possible
(Drummond and McGuire, 2001). Therefore, a country-specific
literature search was performed to identify local costs from official
price lists in England.
Additional estimates came from a Delphi panel, which
allowed expert opinions to be gained on treatment patterns
and associated health care utilization in the absence of robust
published data. The panel was made up of seven medical
specialists practicing in England, who covered the disciplines
of internal medicine, gastroenterology, and medical microbi-
ology. All had clinical experience of managing AAD. They
FIGURE 1 | Structure of the model used in the analysis.
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answered questions in an ad-hoc developed survey on occur-
rence, treatment patterns, and therapeutic modalities associ-
ated with recurrences and complications. The survey instru-
ment was reviewed by the York Health Economic Consortium
before use.
Probabilities
While some prospective studies on the health benefits of probi-
otics in AAD have been conducted, our searches identified only
one conducted in England (Hickson et al., 2007).
We extrapolated clinical outcome data from this randomized
double blind, placebo controlled trial that presented the same set-
ting as assumed for our model. In the trial of 135 hospitalized
elderly (mean age 74 years), Hickson and colleagues investigated
the efficacy in preventing AAD of a 100 g (97ml) of a FM con-
taining the probiotic Lactobacillus paracasei ssp paracasei CNCM
I-1518—formerly referred to as Lactobacillus casei DN 114001—
given twice a day beginning within 48 h of starting antibiotic
therapy and continued until 1 week after the antibiotic treat-
ment finished. The control group received a placebo without
probiotics. Of the probiotic group, 12% (7/57) developed AAD
compared to 34% (19/56) in the placebo group (P = 0.007).
None of the patients randomized to the FM with probiotic devel-
oped CDAD, while 17% (9/53) in the placebo group developed
CDAD (P = 0.001). There were no adverse events in the probiotic
group.
The incidence of AAD ranges widely, depending on the popu-
lation and type of antibiotic (Surawicz, 2005; Butler et al., 2012).
Our base case analysis is based on a mean incidence of 15%,
with sensitivity analysis conducted on a range of 5 and 25%, as
indicated in literature (Bergogne-Berezin, 2000).
The risk ratio (RR) for the total population from Hickson’s
study was 0.35 (12/34), while the most recent Cochrane meta-
analysis reports a RR of 0.36 (Goldenberg et al., 2013). We
assumed a RR of 0.35 for our base case and conducted a scenario
analysis using a RR of 0.36 from the Cochrane meta-analysis.
CDAD accounts for 5–25% of all cases of AAD (Bergogne-
Berezin, 2000; Barbut et al., 2007). Our base case assumes that
15% of patients who develop AAD will have CDAD. A sensitivity
analysis was based on a range from 10 to 25%. The risk reduction
is applied to this incidence data.
The population in the model was stratified by non-severe and
severe diarrhea based on frequency estimates from the Delphi
panel. CDAD can occur up to 8 weeks after antibiotic therapy
(Bartlett and Gerding, 2008).Of the 15% of patients with AAD
estimated to have CDAD, 26% was estimated to be severe at ini-
tial presentation, with 74% non-severe at the onset, but with
18% of the 74% subsequently becoming severely ill. Of the 85%
non-CDAD cases, 12% were estimated to be severe at onset, with
among the 88% who were non-severe at the onset 12% becoming
severe after diagnosis and treatment (Table 1).
Response to treatment varies significantly between antibiotics,
as well as between patients treated with different classes of antibi-
otics. Clinical resolution of AAD is observed in 80–100% of cases
following interruption or change of antibiotic treatment. Delphi
panel members provided separate estimates for non-CDAD and
CDAD for our model (Table 2). For non-CDAD, the Delphi panel
Table 1 | Distribution of severe and non-severe CDAD and non-CDAD.
Non-severe (%) Severe (%)
Onset of CDAD 74 26
Onset of non-CDAD 88 12
Progression (1st line) from mild to severe
CDAD 18
Non-CDAD 12
Table 2 | Response and recurrence percentages based on Delphi.
CDAD
Response 1st line Response 2nd line Response 3rd line
69% 51% 47%
Non-CDAD
Response 1st line Response 2nd line Response 3rd line
73% 35% 33%
CDAD
Recurrence 1st line Recurrence 2nd line Recurrence 3rd line
22% 35% 35%
Non-CDAD
Recurrence 1st line Recurrence 2nd line Recurrence 3rd line
18% 11% 6%
estimated a 73% response rate to first line treatment and an 18%
recurrence rate, which we used in the base case.
We conducted a sensitivity analysis of non-CDAD treatment
responses for a response rate of 80% based on previous research
findings. We did not include mortality for non-CDAD because
we found no relevant published reports of death, and the Delphi
panel confirmed this.
For CDAD, the Delphi panel indicated a response rate to first
line treatment of 69%, which is used in the base case. As this is
lower than the figures reported in literature, we based a sensi-
tivity analysis on an 80% response rate to assess the uncertainty
associated with this estimate.
The risk of recurrence after a single episode of CDAD is
high. Recurrent CDAD (relapse of diarrhea after initial resolu-
tion of symptoms) usually occurs within 1–3 weeks, but has been
described up 2months after the initial episode (Pépin et al., 2006).
The Delphi panel estimate of recurrence rate is 22% which lies
within the range reported in the literature of 8–50% of patients
over 65 years with severe underlying illness having at least a sec-
ond episode after treatment with metronidazole, and additional
antibiotic use (Shannon-Lowe et al., 2010). The estimates by the
Delphi panel are used for the base case. A sensitivity analysis for
recurrences is based on a range from 8 to 50%.
The Delphi panel estimated a 6.14% mortality rate for CDAD,
similar to the 6.9% reported in a study from Quebec (Miller
et al., 2002). C. difficile causes most of the severe cases of AAD,
and therefore in our model, all mortality data were considered to
relate to C. difficile only and not to other causes of AAD.
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Costs
Calculations of costing were based on official NHS price
lists (British National Formulary, 2009; Department of Health
Reference Costs, 2009/10; PSSRU Unit Costs of Health and Social
Care, 2010) in combination with the information on treatment
modalities as provided by the Delphi panel. Additional expenses
included the cost of the probiotic product.
The cost of the FM containing the probiotic Lactobacillus
paracasei ssp paracasei CNCM I-1518 (Actimel®) is based on
twice-daily intake of one bottle of 100 g and cost of GBP 0.33 ×
per bottle. There was no additional cost for the comparator no
preventive treatment. The clinical effectiveness rates have been
described in the section “probabilities” under Methods. The cost
of hospitalization was based on length of stay and per diem costs.
The length of stay was derived from the Delphi panel and per diem
costs were based on the official NHS price lists
The Delphi panel provided estimates on treatment pathways
and drug prescription: all patients with non-CDAD and CDAD
are treated in line with the NICE guidelines. The cost of drug
treatment included in our model is based on the average of
the indications provided by the Delphi panel members and
included the options of stop of antibiotic treatment and switch
of medication.
Management of AAD frequently increases the length of hospi-
tal stays. The additional length of stay and other related resource
utilization were derived from the Delphi panel. The Delphi esti-
mates on treatment modalities for an episode of non-severe,
severe and recurrent AAD, and associated costs are provided in
Tables 3–5, respectively. Table 6 lists the unit costs.
RESULTS
The base case shows that when the FM with probiotic is used,
£243 is saved on average per case treated with antibiotics by pre-
venting non-CDAD, whereas £96 is saved on average per case
treated with antibiotics through preventing CDAD (Table 7).
Although the cost impact for CDAD is much higher, the total
cost savings for CDAD are lower than for non-CDAD because its
represents only 15% of the total AAD cases that occur in older
hospitalized patients receiving antibiotics. The overall results for
both non-CDAD and CDAD show that the mean cost of manag-
ing a case of AAD without using a probiotic preventive strategy is
£555 per patient, whereas the mean cost is £216 per patient when
the probiotic preventive strategy is used. The probiotic interven-
tion therefore leads to potential total mean cost savings of £339
per hospitalized patient over 65 years treated with antibiotics,
regardless of whether he/she develops AAD.
SENSITIVITY ANALYSES
Sensitivity analyses on the incidence of AAD, the propor-
tion of CDAD, the proportion of patients who develop non-
severe/severe AAD, risk reduction based on the meta-analyses,
and estimated response rates and recurrence (Table 8) show
that the cost savings are sensitive to the incidence of AAD
(£100–£576) and to the proportion non-severe/severe patients
(£283–£638). A sensitivity analysis based on risk ratio from
the most recent Cochrane meta-analysis showed an estimated
cost savings of £332 for all forms of AAD. The outcomes
remain cost saving in all the sensitivity analyses undertaken.
Table 3 | Costs in GBP based on Delphi for AAD (non-severe).
Non-severe CDAD Non-CDAD
1st line
Hospitalization £2268 £1614
LOS (in days) 4.3 3.1
Consultations £141 £74
Specialist (number of visits) 2.4 1.4
Other* (number of visits) 2.3 1.6
Medication £35 £1
Other £159 £113
Total £2602 £1802
2nd line
Hospitalization £ 2867 £ 796
LOS (in days) 5.4 1.5
Consultations (same as 1st line) £141 £74
Medication £96 £5
Total £3104 £875
3rd line
Hospitalization £2513 £627
LOS (in days) 4.8 1.2
Consultations (same as 1st line) £141 £74
Medication £154 £1
Total £2808 £702
LOS, length of stay.
*Microbiology, GP, junior doctor, district nurse, pharmacist, consultant,
gastro-enterologist.
These analyses indicate that the FM with probiotic is cost-
effective by preventing AAD in comparison to no preventive
strategy.
DISCUSSION
In our study, we developed a decision analytic core model to
estimate the health economic impact of a FM containing the pro-
biotic L. paracasei CNCM I-1518 for the prevention of AAD in
patients hospitalized aged over 65 years, in England. The rational
for performing this health economic analysis is that the incidence
of AAD has a high impact on the health care resources used.
Therefore, interventions to prevent AAD may have an important
health economic impact.
This analysis has some limitations. First of all, our Delphi
panel made specific estimates for England based on experiences
from their daily practice. As treatment with antibiotics and the
success rates are often country-specific, this may explain some
differences between the estimates from ourDelphi panel and find-
ings from international research. For example, the Delphi panel
estimated a 73% response rate for treatment of AAD, which is
lower than estimates from empirical studies. Sensitivity analyses
performed on the input variables to assess the level of uncertainty
associated with response and recurrences showed that the cost
savings estimates are sensitive to the incidence of AAD, and the
proportion of patients with severe AAD. However, the direction
of outcomes of the model remained consistent in all sensitivity
analyses, which confirms the robustness of the model.
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Table 4 | Costs in GBP based on Delphi for AAD (severe).
Severe CDAD Non-CDAD
1st line
Hospitalization £5688 £2897
LOS (in days) 10.7 5.5
Consultations £192 £147
Specialist (number of visits) 4.1 5.4
Other* (number of visits) 4.0 5.3
Medication £93 £2
Other £319 £242
Total £6292 £3287
2nd line
Hospitalization £5953 £3441
LOS (in days) 11.2 6.6
Consultations (same as 1st line) £192 £147
Medication £90 £30
Total £6236 £3617
3rd line
Hospitalization £4702 £3074
LOS (in days) 8.9 5.9
Consultations (same as 1st line) £192 £147
Medication £216 £15
Total £5110 £3235
LOS, length of stay.
*Microbiology, GP, junior doctor, district nurse, pharmacist, consultant, gastro-
enterologist.
Table 5 | Costs in GBP based on Delphi for AAD (recurrence).
Non-severe Severe
CDAD £ Non-CDAD £ CDAD £ Non-CDAD £
1st line recurrence 3079 871 6237 3610
2nd line recurrence 3127 881 6286 3633
3rd line recurrence 3236 874 6416 3806
Secondly, one may question the relevance of considering the
cost-effectiveness of a preventive probiotic strategy in AAD, given
the on-going debate on the clinical efficacy of probiotics in this
indication and the heterogeneous outcomes. A large multicenter
trial, recently published in Lancet found no differences between
the treatment group and the control group in the incidence of
AAD (Allen et al., 2013). However, this may partly be explained
by the choice of the probiotics used, as well as by the low event rate
(Daneman, 2013), in particular of CDAD. This notwithstanding,
C. difficile infection is the leading cause of diarrhea in industri-
alized countries (Jones et al., 2013) and the Office for National
Statistics states that: “Over 80 per cent of C. difficile infections are
in people aged over 65 years” (www.ons.gov.uk).
This raises the issue of the generalizability from the strict clini-
cal evidence toward health care in real life conditions, comparable
to those reported by Maziade (2013) in an open prospective study
Table 6 | Unit costs in GBP.
Cost £ Fraction Fee £
Specialist 36.5 0.5 73
GP 47 47
Microbiology 43.8 0.3 146
Junior doctors 6.9 0.3
District nurse 10 10
Pharmacist 45 1 45
Consultant 43.8 0.3 146
Gastro-enterologist 43.8 0.3 146
Per diem General ward 530
Single ward 479
Full blood count 3.29
Urea and E 5.72
FBC 5.72
CRP 1.73
Kioch 5.72
WBC 5.72
LFT/UE 5.72
X-abdomen 169
Flex symo 253
Microsopy 11.81
Culture 11.81
Toxin 11.81
Storhs c/S 11.81
Storh WBS 11.81
MC+S 11.81
C. diff PCR 11.81
over a 7-years period, including a total of 31,832 hospitalized
patients receiving antibiotics (Maziade et al., 2013).
Finally, a restriction with regards to external validity is that the
chosen probiotics lactobacilli and bifidobacteria in the study by
Allen are only two types of non-pathogenic bacteria, and there-
fore do not represent daily practice, where much more types of
probiotic strains are used. As a consequence, the results from a
meta-analysis may have a lower internal validity, but on the other
hand have a higher external validity because of the inclusion of
various available probiotic strains. Therefore, the results from the
meta-analysis provide a more profound clinical input for a health
economic analysis.
FM with probiotic, taken as part of the usual meals, also has
nutritional benefits (Radavelli-Bagatini et al., 2013), which can be
of particular importance to the elderly hospitalized population.
The RCT that informed our analysis did not report any adverse
effects related to the dairy product. When adverse effects do occur
with probiotics, they are generally mild and resolve on withdrawal
of the probiotic (Allen et al., 2010; Hempel et al., 2011).
The current health economic analysis is based on a patient-
based cost-effectiveness model. As a consequence the following
clinical and economic issues are not captured in the analysis:
resistance of the antibiotic as such, costs of person-to person
transmission of CDAD, costs associated with isolation of patient,
and closing and cleaning of wards, and transmission.
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Table 7 | Sensitivity analyses.
Cost savings £
Incidence AAD* Base 0.15 339
Low 0.05 101
High 0.25 576
Proportion CDAD* Base 0.15 339
Low 0.1 319
High 0.25 379
Proportion non-severe* Base 0.74 339
Low 0 638
High 1 283
Risk reduction* Base 0.35 339
Cochrane 0.36 332
Response Base: CDAD 0.69 339
Non-CDAD 0.71
Literature*** 0.8 318
Recurrence** Base: CDAD 0.22 339
Non-CDAD 0.17
Low: CDAD 0.08 304
Non-CDAD 0.05
High: CDAD 0.5 407
Non-CDAD 0.42
*Based on literature.
**Based on Delphi.
***Upper limit based on literature; no need for lower range, because this is not
realistic. If literature reports between 80 and 100% response.
Table 8 | Base-case (costs in GBP).
Costs
probiotics £ Other £ Total £ Survival
CDAD
Probiotics 9.24 58.64 67.88 0.9995
No probiotics 0.00 163.98 163.98 0.9986
Difference 96.10 −0.0009
Non-CDAD
Probiotics 9.24 139.07 148.31 1
No probiotics 0.00 391.02 391.02 1
Difference 242.71 0
Total
Probiotics 9.24 206.95 216.19 0.9999
No probiotics 0.00 555.00 555.00 0.9998
Difference 338.81 −0.0001
CONCLUSION
This analysis shows the interest of taking into consideration the
cost-impact of use of a fermented dairy drink containing the
probiotic Lactobacillus paracasei ssp paracasei CNCM I-1518 to
prevent AAD, and in particular CDAD compared to no preven-
tive treatment with probiotics in hospitalized elderly receiving
antibiotics, as this approach potentially allows for considerable
cost savings to the NHS.
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